Barclays’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-63,000
| Closed | -$25.1M | – | 5017 |
|
|
2025
Q4 | $25.1M | Buy |
+63,000
| New | +$27.9M | 0.01% | 1123 |
|
|
2025
Q1 | – | Sell |
-7,300
| Closed | -$1.72M | – | 5248 |
|
|
2024
Q4 | $1.72M | Sell |
7,300
-11,800
| -62% | -$3.1M | ﹤0.01% | 3004 |
|
|
2024
Q3 | $5.25M | Sell |
19,100
-60,400
| -76% | -$15.7M | ﹤0.01% | 2059 |
|
|
2024
Q2 | $19.3M | Buy |
79,500
+50,800
| +177% | +$8.02M | 0.01% | 949 |
|
|
2024
Q1 | $4.29M | Sell |
28,700
-15,700
| -35% | -$2.62M | ﹤0.01% | 1973 |
|
|
2023
Q4 | $8.5M | Buy |
+44,400
| New | +$7.56M | ﹤0.01% | 1638 |
|
|
2023
Q2 | – | Sell |
-45,400
| Closed | -$9.09M | – | 4525 |
|
|
2023
Q1 | $9.09M | Sell |
45,400
-28,100
| -38% | -$5.91M | ﹤0.01% | 1207 |
|
|
2022
Q4 | $17.5M | Buy |
+73,500
| New | +$15.7M | 0.01% | 952 |
|
|
2021
Q3 | – | Sell |
-30,000
| Closed | -$5.09M | – | 4730 |
|
|
2021
Q2 | $5.09M | Buy |
+30,000
| New | +$4.39M | ﹤0.01% | 1574 |
|
|
2021
Q1 | – | Sell |
-600
| Closed | -$78K | – | 4663 |
|
|
2020
Q4 | $78K | Hold |
600
| – | – | ﹤0.01% | 4231 |
|
|
2020
Q3 | $87K | Hold |
600
| – | – | ﹤0.01% | 4321 |
|
|
2020
Q2 | $89K | Sell |
600
-42,100
| -99% | -$5.68M | ﹤0.01% | 4595 |
|
|
2020
Q1 | $4.65M | Sell |
42,700
-28,900
| -40% | -$3.34M | ﹤0.01% | 1532 |
|
|
2019
Q4 | $8.25M | Buy |
71,600
+50,800
| +244% | +$5.06M | ﹤0.01% | 1548 |
|
|
2019
Q3 | $1.67M | Buy |
20,800
+7,000
| +51% | +$554K | ﹤0.01% | 3088 |
|
|
2019
Q2 | $1M | Sell |
13,800
-1,600
| -10% | -$123K | ﹤0.01% | 3684 |
|
|
2019
Q1 | $1.44M | Sell |
15,400
-21,800
| -59% | -$1.82M | ﹤0.01% | 2987 |
|
|
2018
Q4 | $2.71M | Sell |
37,200
-14,500
| -28% | -$1.12M | ﹤0.01% | 2100 |
|
|
2018
Q3 | $4.52M | Sell |
51,700
-14,900
| -22% | -$1.5M | ﹤0.01% | 1912 |
|
|
2018
Q2 | $6.56M | Buy |
66,600
+1,700
| +3% | +$169K | 0.01% | 1520 |
|
|
2018
Q1 | $7.73M | Sell |
64,900
-16,100
| -20% | -$2.08M | 0.01% | 1332 |
|
|
2017
Q4 | $10.3M | Sell |
81,000
-173,800
| -68% | -$21.8M | 0.01% | 1169 |
|
|
2017
Q3 | $29.9M | Buy |
254,800
+92,200
| +57% | +$7.87M | 0.03% | 501 |
|
|
2017
Q2 | $13M | Buy |
162,600
+113,600
| +232% | +$7.26M | 0.01% | 828 |
|
|
2017
Q1 | $2.51M | Buy |
49,000
+40,500
| +476% | +$1.87M | ﹤0.01% | 1868 |
|
|
2016
Q4 | $318K | Sell |
8,500
-7,300
| -46% | -$306K | ﹤0.01% | 3785 |
|
|
2016
Q3 | $1.07M | Sell |
15,800
-6,600
| -29% | -$466K | ﹤0.01% | 2564 |
|
|
2016
Q2 | $1.24M | Buy |
22,400
+8,100
| +57% | +$510K | ﹤0.01% | 2417 |
|
|
2016
Q1 | $887K | Sell |
14,300
-9,600
| -40% | -$638K | ﹤0.01% | 2624 |
|
|
2015
Q4 | $2.25M | Buy |
23,900
+17,600
| +279% | +$1.63M | ﹤0.01% | 1931 |
|
|
2015
Q3 | $504K | Sell |
6,300
-15,400
| -71% | -$1.71M | ﹤0.01% | 3333 |
|
|
2015
Q2 | $2.58M | Buy |
21,700
+9,000
| +71% | +$1.08M | ﹤0.01% | 2017 |
|
|
2015
Q1 | $1.32M | Sell |
12,700
-12,100
| -49% | -$1.23M | ﹤0.01% | 2714 |
|
|
2014
Q4 | $2.41M | Buy |
24,800
+23,100
| +1,359% | +$2.14M | ﹤0.01% | 2356 |
|
|
2014
Q3 | $133K | Sell |
1,700
-21,900
| -93% | -$1.41M | ﹤0.01% | 5097 |
|
|
2014
Q2 | $1.49M | Sell |
23,600
-152,300
| -87% | -$9.05M | ﹤0.01% | 2920 |
|
|
2014
Q1 | $11.8M | Buy |
175,900
+158,600
| +917% | +$12.3M | 0.01% | 1028 |
|
|
2013
Q4 | $1.11M | Buy |
17,300
+9,700
| +128% | +$579K | ﹤0.01% | 3290 |
|
|
2013
Q3 | $486K | Buy |
7,600
+2,800
| +58% | +$140K | ﹤0.01% | 4146 |
|
|
2013
Q2 | $149K | Buy |
+4,800
| New | +$128K | ﹤0.01% | 5452 |
|
Other funds holding ALNY
VPM
VCM
Barclays's ALNY Position: Q1 2026 in Review
Barclays reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.87% in Q1 2026, selling an estimated $659K and leaving 220,623 shares worth $73M. The position accounts for 0.02% of the portfolio, ranked #602.
Barclays first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $88.5M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Barclays held 220,623 shares of Alnylam Pharmaceuticals worth $73M as of Q1 2026.
- Barclays sold 1,938 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $659K.
- Alnylam Pharmaceuticals made up 0.02% of Barclays's portfolio in Q1 2026, its #602 holding.
- Barclays first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Alnylam Pharmaceuticals position peaked at $88.5M in Q4 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.